Aethlon Medical (NASDAQ:AEMD) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Aethlon Medical (NASDAQ:AEMD) in a report released on Saturday. The firm issued a sell rating on the medical equipment provider’s stock.

Separately, HC Wainwright dropped their price target on shares of Aethlon Medical from $10.00 to $7.00 and set a buy rating on the stock in a research note on Monday, June 24th.

Aethlon Medical Stock Performance

AEMD stock opened at $0.42 on Friday. The firm has a market cap of $5.84 million, a P/E ratio of -0.09 and a beta of 1.72. Aethlon Medical has a 1 year low of $0.24 and a 1 year high of $2.47. The stock has a 50-day simple moving average of $0.39 and a 200-day simple moving average of $0.80.

Aethlon Medical (NASDAQ:AEMD) last issued its quarterly earnings data on Wednesday, August 14th. The medical equipment provider reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.10. During the same quarter last year, the company posted ($1.30) earnings per share. On average, equities research analysts predict that Aethlon Medical will post -1.1 EPS for the current year.

About Aethlon Medical

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.